Introduction {#s1}
============

Infectious agents or tissue injury trigger an inflammatory response that aims to eliminate the inciting stressor and restore internal homeostasis ([@bib9]). The mononuclear phagocyte system (MPS) is an integral part of the inflammatory response and consists of the lineage of monocytes and macrophages (MF) and related tissue-resident cells. A key constituent of this system are monocytes of the major (classic) monocyte subtype, in mice called Ly6C^hi^ monocytes. They originate from progenitor cells in the bone marrow (BM), circulate in peripheral blood (PB) and respond dynamically to changing conditions by differentiation into a spectrum of at least three distinct MPS effector phagocytes: Macrophages, dendritic cells (DC), and monocytes with patrolling behavior ([@bib2]; [@bib9]; [@bib12]; [@bib18]; [@bib23]). The diversity of monocyte differentiation responses is thought to be influenced by environmental signals as well as tissue-derived and cell-autonomous signaling mechanisms to ensure context-specific response patterns of the MPS ([@bib35]). However, the precise mechanisms underlying monocyte cell fate decisions under inflammatory conditions are still not fully understood.

When recruited to inflamed or injured tissues, Ly6C^hi^ monocytes differentiate into MF or DC with a variety of phenotypes and function in a context-dependent-manner and regulate the inflammatory response ([@bib28]; [@bib50]). However, Ly6C^hi^ monocytes can also convert to a second, minor subpopulation of monocytes with blood vessel patrolling behavior. In mice, these are called Ly6C^lo^ monocytes and express CD43, CD11c and the transcription factors *Nr4a1*, *Pou2f2* ([@bib18]; [@bib36]; [@bib47]; [@bib52]). These monocytes have a long lifespan and remain mostly within blood vessels, where they crawl along the luminal side of blood vessels to monitor endothelial integrity and to orchestrate endothelial repair ([@bib3]; [@bib10]; [@bib20]). Steady-state monocyte conversion occurs in specialized endothelial niches and is regulated by monocyte Notch2 signaling activated by endothelial Notch ligands ([@bib4]; [@bib7]; [@bib18]; [@bib47]). Notch signaling is a cell-contact-dependent signaling pathway regulating cell fate decisions in the innate immune system ([@bib37]). Notch signaling regulates formation of intestinal CD11c^+^CX~3~CR1^+^ immune cells ([@bib25]), Kupffer cells ([@bib8]; [@bib38]) and macrophage differentiation from Ly6C^hi^ monocytes in ischemia ([@bib28]), but also development of conventional DCs ([@bib11]; [@bib16]; [@bib29]), which is mediated by Notch2.

Toll-like receptor 7 (TLR7) is a member of the family of pathogen sensors expressed on myeloid cells. Originally identified as recognizing imidazoquinoline derivatives such as Imiquimod (R837) and Resiquimod (R848), TLR7 senses ssRNA, and immune-complexes containing nucleic acids, in a Myd88-dependent manner during virus defense, but is also implicated in tissue-damage recognition and autoimmune disorders ([@bib27]). TLR7-stimulation induces cytokine-production in both mouse and human patrolling monocytes and mediates sensing and disposal of damaged endothelial cells by Ly6C^lo^ monocytes ([@bib10]; [@bib14]), while chronic TLR7-stimulation drives differentiation of Ly6C^hi^ monocytes into specialized macrophages and anemia development ([@bib1]). Furthermore, systemic stimulation with TLR7 agonists induces progressive phenotypic changes in Ly6C^hi^ monocytes consistent with conversion to Ly6C^lo^ monocytes, suggesting involvement of TLR7 in monocyte conversion ([@bib40]). Here, we show that Notch signaling alters TLR-driven inflammation and modulates Ly6C^lo^ monocyte vs. macrophage cell fate decisions in inflammation.

Results {#s2}
=======

TLR and Notch signaling promote monocyte conversion {#s2-1}
---------------------------------------------------

We first studied the effects of TLR and/or Notch stimulation on monocyte conversion in a defined in vitro system ([@bib18]). Ly6C^hi^ monocytes isolated from the bone marrow ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}) of *Cx3cr1^gfp/+^* reporter mice (GFP^+^) were cultured with recombinant Notch ligand Delta-like 1 (DLL1) in the presence or absence of the TLR7/8 agonist R848 and analyzed after 24 hr for the acquisition of key features of Ly6C^lo^ monocytes ([@bib18]; [@bib23]). In contrast to control conditions, cells cultured with DLL1 showed an upregulation of CD11c and CD43, remained mostly MHC-II negative, and expressed transcription factors *Nr4a1* and *Pou2f2,* markers for Ly6C^lo^ monocytes, leading to a significant, five-fold increase of Ly6C^lo^ cells, consistent with enhanced monocyte conversion. Cells cultured with R848 alone showed a comparable phenotype response, both qualitatively and quantitatively ([Figure 1A--C](#fig1){ref-type="fig"}). Interestingly, on a molecular level, R848 stimulation primarily acted on *Pou2f2* induction and CD43 expression, while Notch stimulation primarily induced *Nr4a1* and CD11c upregulation. Furthermore, the combination of DLL1 and R848 strongly and significantly increased the number of CD11c^+^CD43^+^ Ly6C^lo^ cells above the level of individual stimulation and significantly enhanced expression levels of both transcriptional regulators *Nr4a1* and *Pou2f2* ([Figure 1A--C](#fig1){ref-type="fig"}), suggesting in part synergistic and/or cumulative regulation of monocyte conversion by TLR7/8 and Notch signaling. By comparison, the TLR4 ligand LPS also increased Ly6C^lo^ cell numbers and expression levels of *Nr4a1* and *Pou2f2*. However, the absolute conversion rate was lower under LPS and there was no synergy/cumulative effect seen with DLL1 ([Figure 1D and E](#fig1){ref-type="fig"}).

![Inflammatory conditions enhance monocyte conversion in vitro.\
(**A--F**) Monocyte conversion in the presence of DLL1 and TLR agonists in vitro: (**A**) Representative flow cytometry plot, (**B**) relative frequency of Ly6C^lo^ monocyte-like cells in live CD11b^+^GFP^+^ cells (left) or absolute numbers of Ly6C^lo^ monocyte-like cells recovered from each well (right) are shown (representative of 3 experiments, n = 3). (**C**) Bar graphs showing expression of Ly6C^lo^ monocyte hallmark genes, *Nr4a1* and *Pou2f2* from in vitro cultures treated with R848 (pooled from four experiments, n = 8--12). (**D**) Relative frequency (in live CD11b^+^GFP^+^ monocytes) or absolute numbers of Ly6C^lo^ monocyte-like cells (from three experiments, n = 3) and (**E**) expression of *Nr4a1* and *Pou2f2* (from four experiments, n = 4--6) in the presence of LPS in vitro are shown. (**F**) wt or *N2^ΔMy^* Ly6C^hi^ monocyte conversion in the presence of DLL1 and R848 in vitro: relative frequency (in live CD11b^+^GFP^+^ monocytes) or absolute numbers of Ly6C^lo^ monocyte-like cells (from three experiments, n = 4) is shown. (**B, D, F**) Absolute frequency of monocytes for Ctrl and DLL1 (in **B, (D**), and wt (Ctrl), wt+DLL1 (Ctrl) in (**F**) conditions are derived from the same experiments but are depicted as a three separate graphs for simplicity.(**G, H**) R848-enhanced conversion is *Myd88* dependent in vitro. Relative frequency (in live CD11b^+^CX~3~CR1^+^ monocytes) or absolute numbers of Ly6C^lo^ monocyte-like cells (**G**) and gene expression analysis in vitro (**H**) are shown (data are from two independent experiments, n = 3). (**B, D, F--H**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; two-way ANOVA with Bonferroni's multiple comparison test. (**C, E**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; paired one-way ANOVA with Geisser-Greenhouse's correction and Bonferroni's multiple comparison test.](elife-57007-fig1){#fig1}

Since monocyte conversion is regulated by Notch2 in vitro and in vivo ([@bib18]), we next tested TLR-induced conversion in Ly6C^hi^ monocytes with *Lyz2^Cre^*-mediated conditional deletion of *Notch2* (*N2^ΔMy^*). Both, littermate control (wt) and *N2^ΔMy^* monocytes showed comparable response to R848, but conversion in the presence of DLL1, and importantly, also DLL1-R848 co-stimulation was significantly impaired in knock-out cells ([Figure 1F](#fig1){ref-type="fig"}). This suggests independent contributions of TLR and Notch signaling to monocyte conversion.

To study whether the TLR stimulation requires Myd88 we next tested purified Ly6C^hi^ monocytes ([Figure 1---figure supplement 1C and D](#fig1s1){ref-type="fig"}) with Myd88 loss-of-function (*Myd88^-/-^*). Compared to wt cells, *Myd88^-/-^* monocytes showed strongly impaired conversion in response to R848 but a conserved response to DLL1. The response to DLL1-R848 co-stimulation, however, was significantly impaired ([Figure 1G](#fig1){ref-type="fig"}). Furthermore, expression of *Nr4a1* and *Pou2f2* by R848 was strongly reduced in *Myd88^-/-^* monocytes with or without DLL1 co-stimulation, while DLL1-dependent induction was preserved ([Figure 1H](#fig1){ref-type="fig"}). Thus, Notch and TLR signaling act independently and synergistically to promote monocyte conversion.

To address the role of TLR stimulation for monocyte conversion in vivo we adoptively transferred sorted Ly6C^hi^ monocytes from CD45.2^+^GFP^+^ mice into CD45.1^+^ congenic recipients, injected a single dose of R848 and analyzed transferred CD45.2^+^GFP^+^ cells in BM and Spl after 2 days ([Figure 2A](#fig2){ref-type="fig"} and [Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}). Stimulation with R848 significantly promoted conversion into Ly6C^lo^ monocytes displaying the proto-typical Ly6C^lo^CD43^+^CD11c^+^MHC-II^lo/-^ phenotype ([Figure 2B and C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In contrast, transfer of *Myd88^-/-^* Ly6 C^hi^ monocytes resulted in impaired conversion in response to R848 challenge ([Figure 2D and E](#fig2){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Together, these data indicate that TLR and Notch cooperate in the regulation of monocyte conversion.

![Inflammatory conditions enhance monocyte conversion in vivo.\
(**A--E**) Adoptive transfer and flow cytometry analysis of BM CD45.2^+^ Ly6C^hi^ monocytes in control or R848 injected CD45.1^+^ congenic recipients: (**A**) Experimental setup is depicted; (**B**) Flow cytometry plots showing the progeny of transferred CD45.2^+^CD11b^+^Ly6C^hi^CX~3~CR1-GFP^+^ (GFP^+^) cells in black and recipient CD45.1^+^ (1^st^ row), CD45.1^+^CD11b^+^ (2^nd^ row) or CD45.1^+^CD11b^+^Ly6C^hi^ cells (3^rd^ −5^th^ rows) in blue; (**C**) Frequency of donor-derived Ly6C^lo^ monocytes pooled from two independent experiments (n = 5). (**D, E**) R848-enhanced conversion is *Myd88* dependent in vivo. (**D**) Flow cytometry plots showing transferred CD45.2^+^CX~3~CR1^+^ wt or *Myd88^-/-^* cells in black and recipient CD45.1^+^CX~3~CR1^+^ (1^st^ row), CD45.1^+^CX~3~CR1^+^CD11b^+^ (2^nd^ row) or CD45.1^+^CX~3~CR1^+^CD11b^+^Ly6C^hi^ cells (3^rd^ −5^th^ rows) in blue. All recipient mice which received wt or *Myd88^-/-^* donor cells were treated with R848; (**E**) Frequency of donor-derived Ly6C^lo^ monocytes pooled from two independent experiments are shown (n = 4/5). (**C, E**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; Student's *t*-test.](elife-57007-fig2){#fig2}

Notch2-deficient mice show altered myeloid inflammatory response {#s2-2}
----------------------------------------------------------------

To characterize the response to TLR stimulation in vivo, we applied the synthetic TLR7 agonist Imiquimod (IMQ, R837) in a commercially available crème formulation (Aldara) daily to the skin of mice ([@bib15]; [@bib45]) and analyzed the systemic inflammatory response in control or *N2^ΔMy^* mice ([@bib18]; [Figure 3A](#fig3){ref-type="fig"}). While treatment with IMQ-induced comparable transient weight loss and ear swelling in both genotypes ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), splenomegaly in response to treatment was significantly more pronounced in *N2^ΔMy^* mice ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

![Acute inflammation triggers altered myeloid cell response in *N2^ΔMy^* mice.\
(**A**) Experimental set-up for IMQ treatment and analysis of mice. (**B, C**) Gating strategy for t-SNE analysis and definition of cell subsets based on expression of surface markers are shown. t-SNE was performed on live CD45^+^Lin^-^CD11b^+^GFP^+^ cells concatenated from 48 PB samples from four independent experiments. (**D**) Unsupervised t-SNE analysis showing composition and distribution of cellular subsets from PB of wt or *N2^∆My^* IMQ-treated or untreated mice at different time points defined in **B, C**) (n = 8 mice are pooled for each condition). (**E, F**) Relative frequency of different myeloid subpopulations in PB and Spl of untreated or IMQ-treated mice are shown (data are pooled from six experiments n = 7--18). (**E, F**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; two-way ANOVA with Bonferroni's multiple comparison test.](elife-57007-fig3){#fig3}

To characterize the spectrum of myeloid cells in more detail, we next performed flow cytometry of PB cells with a dedicated myeloid panel ([@bib18]) in wt or *N2^ΔMy^ Cx3cr1^gfp/+^* mice and subjected live Lin^-^CD11b^+^GFP^+^ subsets to unsupervised t-SNE analysis ([Figure 3B](#fig3){ref-type="fig"}). This analysis strategy defined five different populations, based on single surface markers: Ly6C^+^, CD43^+^, MHC-II^+^, F4/80^hi^ and CD11c^hi^ ([Figure 3C](#fig3){ref-type="fig"}). Applying these five gates to samples from separate experimental conditions identified dynamic alterations in blood myeloid subsets in response to IMQ, but also alterations in *N2^ΔMy^* mice ([Figure 3D](#fig3){ref-type="fig"}). Specifically, abundance and distribution of Ly6C^+^ cells, containing classical monocytes, in response to IMQ were changed to the same extend in both genotypes. In contrast, the MHC-II^+^ and F4/80^hi^ subsets were more abundant in *N2^ΔMy^* mice, but also showed more robust changes in response to IMQ. On the other hand, the CD43^+^ subset, containing the patrolling monocyte subset, showed prominent enrichment in wt mice, but was less abundant and showed diminished distribution changes after IMQ treatment in *N2^ΔMy^* mice ([Figure 3D](#fig3){ref-type="fig"}).

To analyze the initially defined subsets more precisely, we applied a multi-parameter gating strategy to define conventional cell subsets ([Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [@bib18]).

In response to IMQ, Ly6C^hi^ monocytes in wt mice increased transiently in blood, and this response was not altered in mice with conditional *Notch2* loss-of function ([Figure 3E](#fig3){ref-type="fig"}). In contrast, while Ly6C^lo^ monocytes robustly increased over time with IMQ treatment in wt mice, their levels in *N2^ΔMy^* mice were lower at baseline ([@bib18]) and remained significantly reduced throughout the whole observation period ([Figure 3E and F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}). At the same time, while untreated *N2^ΔMy^* mice showed increased levels of MHC-II^+^ atypical monocytes ([Figure 3E and F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}; [@bib18]), IMQ treatment induced the generation of F4/80^hi^CD115^+^ monocytes in the blood and increased MF in the spleen at d5 ([Figure 3E and F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3A and B](#fig3s3){ref-type="fig"}). This was followed by a peak in the DC population at d7 ([Figure 3E and F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3A and B](#fig3s3){ref-type="fig"}). These latter changes did not occur in bone marrow but were only observed in the periphery ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). Together, these data suggest that wt Ly6C^hi^ monocytes convert to Ly6C^lo^ monocytes in response to TLR stimulation, while Notch2 deficient Ly6C^hi^ monocytes differentiate into F4/80^hi^CD115^+^ monocytes, macrophages and DC, suggesting Notch2 as a master regulator of Ly6C^hi^ monocyte cell fate during systemic inflammation.

Global gene expression analysis identifies macrophage gene expression signatures in monocytes of Notch2-deficient mice during acute inflammation {#s2-3}
------------------------------------------------------------------------------------------------------------------------------------------------

To characterize more broadly the gene expression changes involved in monocyte differentiation during inflammation, we next subjected monocyte subsets from PB of wt and *N2^ΔMy^* mice after Sham or IMQ treatment ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) to RNA-sequencing and gene expression analysis. After variance filtering and hierarchical clustering, 600 genes were differentially expressed between six experimental groups ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}).

![Enhanced macrophage gene expression signatures in monocytes and altered inflammatory response in *N2^ΔMy^* mice.\
(**A, B**) Hierarchical clustering of 600 ANOVA-selected DEGs (**A**) and PCA of PB monocyte subsets (**B**) after IMQ treatment (n = 4) is shown (Variance filtering 0.295, ANOVA followed by the B-H correction (p\<0.0076, FDR ≤ 0.01)). (**C**) Hierarchical clustering of 373 DEGs from IMQ-treated wt and *N2^ΔMy^* Ly6C^lo^ monocyte subsets (Variance filtering 0.117,--0.6≥Δlog~2~ ≥ 0.6, Student's *t*-test with B-H correction (p\<0.01, FDR ≤ 0.05)). (**D**) Volcano plot showing 379 DEGs between wt and *N2^ΔMy^* Ly6C^lo^ cells (-log10(p-value) ≥ 2, FDR ≤ 0.05, light blue); and 87 DEGs (−1≥Δlog~2~ ≥ 1 (FDR ≤ 0.01) purple); genes of interest are marked black (Student's *t*-test with B-H correction). (**E**) Heat map of top 38 DEGs from (**D**) log10(﻿p-value) ≥ 4,--1≥Δlog~2~ ≥ 1, Student's *t*-test with B-H correction. (**F**) Bar graph showing mean number and SEM of sequence reads for selected genes from IMQ-treated wt and *N2^ΔMy^* Ly6C^lo^ cell subsets. (**G**) Analysis of cytokine and chemokine profiles in the serum of IMQ-treated mice. n = 5--10, pooled from four independent experiments. (**G**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; 2way ANOVA with Bonferroni's multiple comparison test.\
Figure 4---source data 1.List of 600 DEGs for hierarchical clustering and PCA ([Figure 4A and B](#fig4){ref-type="fig"}) from Ly6C^hi^ and Ly6C^lo^ subpopulations isolated from sham-or IMQ(Aldara)-treated wt or *N2^ΔMy^* mice.\
Figure 4---source data 2.List of 373 DEGs between Ly6C^lo^ cells isolated from IMQ(Aldara)-treated wt or *N2^ΔMy^* mice and used for the analysis in [Figure 4C and D](#fig4){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}--[5](#supp5){ref-type="supplementary-material"}.](elife-57007-fig4){#fig4}

Principal component analysis (PCA) of differentially expressed genes (DEG) of all experimental groups revealed a clear separation between control Ly6C^hi^ monocytes and IMQ-treated Ly6C^hi^ or Ly6C^lo^ monocytes. Interestingly, the effects of *Notch2* loss-of-function were most pronounced in the Ly6C^lo^ populations, which separated quite strongly depending on genotype, while Ly6C^hi^ monocytes from wt and *N2^ΔMy^* mice over all maintained close clustering under Sham or IMQ conditions ([Figure 4B and C](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}).

Furthermore, while wt Ly6C^lo^ cells were enriched for genes characteristic of patrolling monocytes (*Hes1, Nr4a1*, *Ace*, *Cd274 and Itgb3*), cells in the Ly6C^lo^ gate from *N2^ΔMy^* mice showed upregulation of genes characteristic of mature phagocytes, such as MF (*Fcgr1, Mertk, C1qa, Clec7a, Maf, Cd36, Cd14, Adgre1* (encoding F4/80)) ([Figure 4D--F](#fig4){ref-type="fig"}).

Comparative gene expression analysis of Ly6C^lo^ cell subsets during IMQ treatment identified 373 genes significantly up- or down-regulated with Notch2 loss-of-function (p-value\<0.01, [Figure 4C--F](#fig4){ref-type="fig"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}), which were enriched for phagosome formation, complement system components, Th1 and Th2 activation pathways and dendritic cell maturation by ingenuity canonical pathway analysis ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Notably, signatures for autoimmune disease processes were also enriched ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Independent gene set enrichment analysis (GSEA) ([@bib24]; [@bib34]) confirmed consistent up-regulation of gene sets in *N2^ΔMy^* Ly6C^lo^ cells involved in several gene ontology biological processes, such as vesicle-mediated transport (GO:0016192), defense response (GO:0006952), inflammatory response (GO:0006954), response to bacterium (GO:0009617) and endocytosis (GO:0006897) ([Supplementary file 3](#supp3){ref-type="supplementary-material"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). Overall, these data suggest regulation of Ly6C^hi^ monocyte cell fate and inflammatory responses by Notch2.

Furthermore, changes in cell populations resulted in altered systemic inflammatory response patterns. Levels of TLR-induced cytokines and chemokines, such as TNF-α, CXCL1, IL-1β, IFN-α, were elevated to the same extend in wt and *N2^ΔMy^* mice in response to IMQ treatment, suggesting normal primary TLR-activation ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). However, circulating levels of chemokines produced by Ly6C^lo^ monocytes ([@bib10]), such as CCL2, CCL3, CXCL10, and IL-10 were higher in wt mice compared to *N2^ΔMy^* mice, while the levels of pro-inflammatory cytokines IL-17A, IL-6 and GMCSF were significantly enhanced in *N2^ΔMy^* mice but not in wt mice as compared to untreated controls, confirming systemic alterations in addition to cellular changes in *Notch2* loss-of-function mice in response to IMQ ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).

Notch2-deficiency promotes macrophage differentiation {#s2-4}
-----------------------------------------------------

To match the observed gene expression pattern of inflammatory Ly6C^lo^ cells from wt and *N2^ΔMy^* mice under IMQ treatment with previously described cells of the monocyte-macrophage lineage we performed pairwise gene set enrichment analysis with defined myeloid cell transcriptomic signatures using the GSEA software and BubbleGUM stand-alone software ([@bib24]; [@bib34]; [@bib43]; [Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"} and [5](#supp5){ref-type="supplementary-material"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). Out of 29 transcriptomic signatures - representing tissue MF, monocyte derived DC (MoDC), conventional DC (cDC), plasmacytoid DC (pDC), classical (Ly6C^hi^) monocytes (cMonocyte), non-classical (Ly6C^lo^) monocytes (ncMonocyte) and B cells (as a reference) -- significant enrichment was registered in seven signatures (normalized enrichment score (NES \>1.5, FDR \< 0.1)). The cell fingerprint representing ncMonocyte (\#3) was highly enriched in the gene set from wt Ly6C^lo^ monocytes (NES = 1.91, FDR = 0.039), while all other cell fingerprints showed no significant similarity ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}), confirming a strong developmental restriction toward Ly6C^lo^ monocytes in wt cells. In contrast, *N2^ΔMy^* gene sets showed the highest similarity (NES \>1.8 and FDR \< 0.01) with four cell fingerprints (\#1, 5, 6, 7) representing different MF populations, and weak similarity to MoDC (NES = 1.64, FDR \< 0.1) and cMonocyte (NES = 1.54, FDR \< 0.1) ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary files 4](#supp4){ref-type="supplementary-material"} and [5](#supp5){ref-type="supplementary-material"}). Phenotyping of cell populations by flow cytometry using MF markers MerTK and CD64 ([Figure 5B--D](#fig5){ref-type="fig"}) confirmed selective expansion of an F4/80^hi^MerTK^+^ (FM^+^) monocyte population in IMQ-treated *N2^ΔMy^* mice ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary files 4](#supp4){ref-type="supplementary-material"} and [5](#supp5){ref-type="supplementary-material"}). Together, these data demonstrate a cell fate switch from Ly6C^lo^ monocytes toward macrophage signatures in the absence of Notch2.

![Notch2-deficient Ly6C^lo^ cells show enhanced macrophage maturation during acute inflammation.\
(**A**) GSEA based on 373 DEGs between IMQ-treated wt and *N2^ΔMy^* Ly6C^lo^ subsets in PB. Red -- positive-, and blue - negative enrichment in corresponding color-coded wt or *N2^ΔMy^* cells. Size of the circle corresponds to NES and intensity of the color to FDR. (**B, C**) Representative flow cytometry plots showing expression of F4/80 and MerTK in gated Lin^-^CD45^+^CD11b^+^GFP^+^Ly6C^hi^ and Lin^-^CD45^+^CD11b^+^GFP^+^Ly6C^lo^ cells from PB of Sham- or IMQ-treated wt or *N2^ΔMy^* mice. (**D**) Representative flow cytometry histograms with corresponding mean fluorescence intensities (MFI) showing expression of CD64 on myeloid cells in PB of sham or IMQ-treated mice. (**E**) Flow cytometry analysis 3 days after adoptive transfer of wt or *N2^∆My^* BM CD45.2^+^ Ly6C^hi^ monocytes in IMQ-treated CD45.1^+^ recipients. Transferred cells are shown in black and recipient CD45.1^+^ (1^st^ row), CD45.1^+^CD11b^+^ (2^nd^ row) or CD45.1^+^CD11b^+^Ly6C^hi^ cells (3^rd^ −5^th^ rows) are depicted in blue. (**F, G**) Frequency of donor-derived Ly6C^lo^ monocytes (**G**) or macrophages (**H**) in CD45.2^+^CD11b^+^GFP^+^ donor cells after adoptive transfer of wt or *N2^∆My^* Ly6C^hi^ monocytes is shown. Data are pooled from three independent experiments (n = 6/9). (**H**) Relative (top) and absolute number (bottom) of myeloid subpopulations in aortas of untreated or IMQ-treated mice. Data are pooled from six experiments (n = 7--18). (**J, K**) Representative flow cytometry plot of donor CD11b^+^GFP^+^ cells (**J**) and relative frequency of donor-derived macrophages (**K**) within CD45.2^+^CD11b^+^GFP^+^ cells recovered from aortas after adoptive transfer of wt or *N2^∆My^* Ly6C^hi^ monocytes. (**K**) Data are pooled from three independent experiments (n = 9). (**L, M**) Relative frequency of apoptotic (AnnexinV^+^PI^neg^) cells in each myeloid subpopulation isolated from PB or BM of Sham- or IMQ-treated mice is shown (Data are from two independent experiments (n = 6--7)). (**F, G, K**) \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; Student's *t*-test. (**H, L, M**) \*\*p\<0.01, \*\*\*p\<0.001; two-way ANOVA with Bonferroni's multiple comparison test.](elife-57007-fig5){#fig5}

Notch2 regulates monocyte cell fate decisions during inflammation {#s2-5}
-----------------------------------------------------------------

In the steady-state, Ly6C^hi^ monocytes differentiate into Ly6C^lo^ monocytes and this process is regulated by Notch2 ([@bib18]). In order to confirm that Notch2 controls differentiation potential of Ly6C^hi^ monocytes in response to TLR stimulation, we performed adoptive transfer of CD45.2^+^ wt or *N2^ΔMy^* BM Ly6C^hi^ monocytes into IMQ-treated CD45.1^+^ congenic recipients and analyzed the fate of donor cells after 3 days ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Unsupervised t-SNE analysis of flow cytometry data showed an expanded spectrum of expression patterns in cells from *N2^ΔMy^* donors compared to wt controls ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). More precisely, Ly6C^hi^ monocytes from wt mice converted preferentially to Ly6C^lo^ monocytes (Ly6C^lo^F4/80^lo/-^CD11c^+^CD43^+^MHC-II^lo/-^ phenotype) during IMQ treatment ([Figure 5E and F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). In contrast, conversion of Notch2-deficient Ly6C^hi^ to Ly6C^lo^ monocytes was strongly impaired, but the development of donor-derived F4/80^hi^ macrophages in the spleen was strongly enhanced ([Figure 5G](#fig5){ref-type="fig"}). Furthermore, expansion of macrophages was also observed in aortas of Notch2 deficient mice in vivo after IMQ treatment ([Figure 5H](#fig5){ref-type="fig"}). Adoptive transfer studies confirmed that MF in IMQ-treated aortas originated from *N2^ΔMy^* Ly6C^hi^ monocytes ([Figure 5J and K](#fig5){ref-type="fig"}).

To evaluate Notch targeting efficiency in our system we performed flow cytometry and transcriptome analysis of transgenic monocyte subsets. In Ly6C^hi^ monocytes, the *Lyz2^Cre^*-mediated conditional deletion strategy induced a 40--50% reduction of Notch2 expression by flow cytometry and transcriptome analysis ([Figure 5---figure supplement 2A and C](#fig5s2){ref-type="fig"}), and a \> 50% reduction of Notch target gene *Hes1*, demonstrating partial targeting and functional impairment of Notch2 in Ly6C^hi^ monocytes ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). At the same time, in Ly6C^lo^ monocytes at baseline there was only minor reduction of Notch2, corroborating earlier results ([@bib18]), but more efficient reduction of Notch2 in IMQ-treated mice to levels seen in Ly6C^hi^ monocytes ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}). Furthermore, levels of Notch target gene *Hes1* were low in Ly6C^hi^ monocytes but significantly increased in Ly6C^lo^ monocytes ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}; [@bib18]), suggesting low Notch signaling in Ly6C^hi^ monocytes but higher Notch signaling activity in Ly6C^lo^ monocytes.

Since Ly6C^lo^ monocyte deficiency in *Nr4a1*-deficient mice is caused by increased apoptosis ([@bib22]), we analyzed cells by AnnexinV staining. Notch2-deficiency did not significantly increase cell death in all analyzed cell populations, neither during steady state nor during inflammation ([Figure 5L and M](#fig5){ref-type="fig"}).

Together, these data confirm that Notch2 is a master regulator of Ly6C^hi^ monocyte differentiation potential, regulating a switch between Ly6C^lo^ monocyte or macrophage cell fate during inflammation. These data also demonstrate that in the context of inactive myeloid Notch2 signaling, TLR-stimulation results in systemic pro-inflammatory changes and vascular inflammation.

Discussion {#s3}
==========

Together, our data present a spectrum of developmental cell fates of Ly6C^hi^ monocytes and their coordinated regulation by TLR and Notch signaling during inflammation. TLR and Notch signaling act independently and synergistically in promoting Ly6C^lo^ monocyte development from Ly6C^hi^ monocytes, while impairment in either signaling axis impairs Ly6C^lo^ monocyte development. On the other hand, TLR stimulation in the absence of functional Notch2 signaling promotes macrophage gene expression signatures in monocytes and development of MF in aorta and spleen, suggesting Notch2 as a master regulator of Ly6C^hi^ monocyte cell fate during systemic inflammation.

Plasticity of Ly6C^hi^ monocytes ensures adaptation to environmental signals, which trigger distinct cell developmental programs inducing context- or tissue-specific subsets of terminally differentiated phagocytes, including Ly6C^lo^ monocytes, MF or DC ([@bib21]). In the steady-state, a subset of Ly6C^hi^ monocytes converts to Ly6C^lo^ monocytes in mice and humans, which is regulated by Notch2 and the endothelial Notch ligand Delta-like 1 (Dll1) ([@bib18]; [@bib36]; [@bib52]). However, when recruited into tissues, Ly6C^hi^ monocytes can give rise to two types of monocyte-derived resident tissue macrophages (MRTM) ([@bib12]). These Lyve1^hi^MHC-II^lo^ and Lyve1^lo^MHC-II^hi^ MRTMs differ in phenotype and function as well as spatial distribution. Our gene set enrichment analysis revealed that the signature of cells from inflamed wt mice showed highest and selective similarity to non-classical Ly6C^lo^ monocytes, while *Notch2* loss-of-function cells showed the highest similarity to the gene set of Lyve1^hi^MHC-II^lo^ MRTM, but also a more general similarity to an extended spectrum of different MF signatures, suggesting Notch2 as a gate keeper of Ly6C^lo^ monocytes vs. macrophage differentiation during inflammation. Due to the low number Ly6C^lo^ monocytes at the steady state, we were not able to compare baseline expression profiles, which is a limitation of this analysis. Lyve1^hi^MHC-II^lo^ interstitial MFs are closely associated with blood vessels across different tissues and mediate inflammatory reactions ([@bib12]). In line with this, *Notch2* knock-out mice showed a population of FM^+^ monocytes with partial gene expression signatures of MF circulating in the blood and increased MF in the aorta, and adoptive transfer studies of Ly6C^hi^ monocytes successfully recapitulated their differentiation into aortic MF. These data also have implications for the potential developmental regulation of MRTMs by TLR and Notch2. At the same time, the Notch2-deficient population showed weaker but significant enrichment of MoDC signatures, suggesting a mixture of cell subsets representing different stages of monocyte differentiation ([@bib32]; [@bib33]) or lineage commitment ([@bib31]; [@bib51]) within this cell pool, although formally we cannot exclude progenitor contamination as a confounder in our adoptive cell transfer studies.

The *Lyz2^Cre^*-mediated conditional deletion strategy induced a 40--50% reduction of Notch2 expression, and a \> 50% reduction of Notch target gene *Hes1* in Ly6C^hi^ monocytes, suggesting sufficient targeting and functional impairment of Notch2. Nevertheless, partial targeting might explain the small differences seen in PCA analysis in these cells. However, in light that baseline Notch signaling activity seems to be low in Ly6C^hi^ monocytes and only significantly increases in Ly6C^lo^ monocytes ([@bib18]), it suggests that Notch2 influences cell fate decision in Ly6C^hi^ monocytes or at the early stages of conversion to Ly6C^lo^ monocytes. Furthermore, the fact that there is only a minor reduction of Notch2 in Ly6C^lo^ monocytes at baseline, which suggests a strong selection bias against *Notch2* loss-of-function, further argues for a strict Notch2-dependence of monocyte conversion.

In the case of *Nr4a1* loss-of-function, the reduced numbers of Ly6C^lo^ monocytes are due to increased apoptosis ([@bib22]). Although we did not find evidence for increased apoptosis due to Notch2-deficiency, our data do not exclude the possibility that regulation of cell survival by Notch2 contributes to the observed phenotype. In fact, two lines of the evidence suggest that regulation of cell survival might act synergistically to cell fate choices: first, in absolute numbers, there is no compensation by alternative cell fates for the number of lacking Ly6C^lo^ monocytes in the blood or spleen of *N2^ΔMy^* mice; second, expression of *Bcl2*, a strong regulator of cell survival, is downregulated in IMQ-treated *N2^ΔMy^* Ly6C^lo^ cells as compared to controls.

While our current data clearly demonstrate that *Notch2* loss-of-function promotes macrophage gene expression profiles in monocytes and macrophage development from Ly6C^hi^ monocytes during TLR stimulation, we have previously shown that Dll1-Notch signaling promotes maturation of anti-inflammatory macrophages from Ly6C^hi^ monocytes in ischemic muscle ([@bib28]). Furthermore, Dll4-Notch signaling initiated in the liver niche was recently shown to promote Kupffer cell development after injury ([@bib8]; [@bib38]) or to promote pro-inflammatory macrophage development ([@bib49]). This suggests that the role of Notch is ligand-, cell- and context-specific, which emphasizes the differential effects of specific ligand-receptor combinations ([@bib5]). Our data demonstrate that Notch2 is a master regulator of Ly6C^hi^ monocyte cell fate during inflammation, which contributes to the nature of the inflammatory response.

Lastly, our data also reveal a potentially important function of myeloid Notch2 for regulation of systemic and vascular inflammation with implications for autoimmune disease. When wt mice are challenged with TLR stimulation they show predominant conversion of Ly6C^hi^ monocytes into Ly6C^lo^ monocytes with blood vessel patrolling and repairing function ([@bib10]) and IL-10 secretion. In contrast, *Notch2* knock-out mice show predominant and ectopic differentiation of Ly6C^hi^ monocytes into FM^+^ monocytes and macrophages, which appear in the bloodstream and the spleen and infiltrate major blood vessels, such as the aorta, along with aberrant cytokine profiles. In addition, absence of functional Notch2 promoted a core macrophage signature and strong upregulation of canonical pathways involved in autoimmune disease. Since TLR7 has been implicated in the development of autoimmune disease ([@bib40]; [@bib39]), our data suggest Notch2 as an important modulator of this process by regulating cell differentiation and systemic inflammation. However, the relevance and possible disease context requires further studies.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

B6.129P-*Cx3cr1^tm1Litt^*/J (*Cx3cr1^GFP/+^*) mice ([@bib26]), B6.129P2-*Lyz2^tm1(cre)Ifo ^(Lyz2^Cre^*) mice ([@bib13]), B6.129-*Notch2^tm1Frad^*/J (*Notch2^lox/lox^*) mice ([@bib6]), B6.129-*Lyz2^tm1(cre)Ifo^Notch2^tm1Frad^Cx3cr1^tm1Litt^* (*N2^ΔMy^*) ([@bib18] have been previously described. B6.SJL*-Ptprc^a^Pepc^b^/*BoyJ (CD45.1^+^) mice were from central animal facility of Hannover Medical School (ZTL, MHH). B6.129P2-*Myd88^tm1Hlz^*/J (*Myd88^-/-^*) ([@bib17]) and *Myd88^+/+^* littermate control (wt) mice were kindly provided by Dr. Matthias Lochner. Mice were housed under specific pathogen-free conditions in the animal facility of Hannover Medical School.

Tissue and cell preparation {#s4-2}
---------------------------

For single cell suspension mice were sacrificed and spleen, bone marrow, blood and aortas were collected. Erythrocytes were removed by red blood cell lysis buffer (BioLegend) or by density gradient centrifugation using Histopaque 1083 (Sigma-Aldrich). Aortas were digested in DMEM medium supplemented with 500 U/ml Collagenase II (Worthington). After extensive washing, cells were resuspended in PBS containing 10%FCS and 2 mM EDTA kept on ice, stained and used for flow cytometry or for sorting.

Flow cytometry and cell sorting {#s4-3}
-------------------------------

Non-specific binding of antibodies to Fc-receptors was blocked with anti-mouse CD16/CD32 (TruStain fcX from BioLegend) in single-cell suspensions prepared from Spl, PB or BM. After subsequent washing step, cells were labeled with primary and secondary antibodies or streptavidin-fluorochrome conjugates and were used for flow cytometry analysis (LSR-II, BD Biosciences) or sorting (FACSAria; BD Biosciences or MoFlo XDP; Beckman Coulter).

For apoptosis assay, single-cell suspensions were stained with primary and secondary antibodies, washed, re-suspended in AnnexinV binding buffer (Biolegend) and transferred into tubes. Cells were stained with AnnexinV (AnnV) and propidium iodide (PI) at room temperature for 20 min and were immediately analyzed by flow cytometry. Antibodies and fluorochromes used for flow cytometry are described in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. Flow cytometry data were analyzed using FlowJo software (FlowJo LLC). Initially cells were identified based on FSC and SSC characteristics. After exclusion of doublets (on the basis of SSC-W, SSC-A), relative frequency of each subpopulation from live cell gate, or absolute number of each subset (calculated from live cell gate and normalized per Spl, per mg Spl, mg BM, mg aorta or µl PB) were determined and are shown in the graphs as mean ± SEM, unless otherwise stated. Unsupervised t-distributed stochastic neighbor embedding (t-SNE) analysis ([@bib46]) was performed on live CD45^+^Lin^-^GFP^+^CD11b^+^ population in concatenated samples using FlowJo.

Cytokine multiplex bead-based assay {#s4-4}
-----------------------------------

Sera were collected from control or Aldara treated mice and kept frozen at −80°C. Concentration of IFN-γ, CXCL1, TNF-α, CCL2, IL-12(p70), CCL5, IL-1β, CXCL10, GM-CSF, IL-10, IFN-β, IFN-α, IL-6, IL-1α, IL-23, CCL3, IL-17A were measured with LEGENDplex multi-analyte flow assay kits (BioLegend) according to manufacturer's protocol on LSR-II flow cytometer. Data were processed and analyzed with LEGENDplex data analysis software (BioLegend).

RNA isolation, library construction, sequencing and analysis {#s4-5}
------------------------------------------------------------

Peripheral blood monocyte subpopulations were sorted from Aldara treated mice or untreated controls ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and RNA was isolated using RNeasy micro kit (Qiagen). Libraries were constructed from total RNA with the 'SMARTer Stranded Total RNA-Seq Kit v2 -- Pico Input Mammalian' (Takara/Clontech) according to manufacturer's recommendations, barcoded by dual indexing approach and amplified with 11 cycles of PCR. Fragment length distribution was monitored using 'Bioanalyzer High Sensitivity DNA Assay' (Agilent Technologies) and quantified by 'Qubit dsDNA HS Assay Kit' (ThermoFisher Scientific). Equal molar amounts of libraries were pooled, denatured with NaOH, diluted to 1.5pM (according to the Denature and Dilute Libraries Guide (Illumina)) and loaded on an Illumina NextSeq 550 sequencer for sequencing using a High Output Flowcell for 75 bp single reads (Illumina). Obtained BCL files were converted to FASTQ files with bcl2fastq Conversion Software version v2.20.0.422 (Illumina). Pre-processing of FASTQ inputs, alignment of the reads and quality control was conducted by nfcore/rnaseq (version 1.5dev) analysis pipeline (The National Genomics Infrastructure, SciLifeLab Stockholm, Sweden) using Nextflow tool. The genome reference and annotation data were taken from [GENCODE.org](http://gencode.org/) (GRCm38.p6 release M17). Data were normalized with DESeq2 (Galaxy Tool Version 2.11.39) with default settings and output counts were used for further analysis with Qlucore Omics explorer (Sweden). Data were log~2~ transformed, 1.1 was used as a threshold and low expression genes (\<50 reads in all samples) were removed from the analysis. Hierarchical clustering (HC) or principal component analysis (PCA) was performed on 600 differential expressed genes (DEGs) after variance filtering (filtering threshold 0.295) selected by ANOVA with the Benjamini-Hochberg (B-H) correction (p\<0.01, FDR ≤ 0.01). For two group comparisons Student's *t*-test with B-H correction was used and 373 DEGs ((Variance filtering 0.117,--0.6≥Δlog~2~ ≥0.6 (p\<0.01, FDR ≤ 0.05)) were selected for further IPA or GSEA analysis.

Ingenuity pathway analysis (IPA) was performed on 373 DEGs using IPA software (Qiagen) with default parameters. Top 20 canonical pathways and top five immunological diseases enriched in DEGs were selected for display.

Gene set enrichment analysis (GSEA) ([@bib34]; [@bib44]) was performed on 373 DEGs using GSEA software (Broad institute) and C5 GO biological process gene sets ([@bib30]) from MsigDB with 1000 gene set permutations for computing p-values and FDR.

BubbleGUM software, an extension of GSEA ([@bib43]; [@bib48]), GSEA software (Broad Institute) and published transcriptomic signatures ([@bib12]; [@bib19]; [@bib41]; [@bib48]) were used to assess and visualize the enrichment of obtained gene sets for myeloid populations and define the nature of the cells from which the transcriptomes were generated.

In vitro conversion studies {#s4-6}
---------------------------

96-well flat bottom plates were coated at room temperature for 3 hr with IgG-Fc or DLL1-Fc ligands (all from R and D) reconstituted in PBS. Sorted BM Ly6C^hi^ monocytes were cultured in coated plates and were stimulated with Resiquimod (R848, 0.2 µg ml^−1^, Cayman Chemicals) or LPS (0.2 µg ml^−1^, *E. coli* O55:B5 Sigma-Aldrich) in the presence of M-CSF (10 ng ml^−1^, Peprotech) at 37°C for 24 hr. One day after culture, cells were harvested, stained and subjected to flow cytometry. Relative frequency (from total live CD11b^+^GFP^+^ cells) or absolute numbers of Ly6C^lo^ monocyte-like cells (CD11b^+^GFP^+^Ly6C^lo/-^CD11c^lo^MHC-II^lo/-^CD43^+^) recovered from each well served as an indicator of conversion efficiency and is shown in the graphs. Alternatively, cultured cells were harvested and isolated RNA was used for gene expression analysis.

Induction of acute systemic inflammation using IMQ {#s4-7}
--------------------------------------------------

Mice were anesthetized and back skin was shaved and depilated using depilating crème. Two days after 50 mg/mouse/day Aldara (containing 5% Imiquimod, from Meda) or Sham crème were applied on depilated skin and right ear (where indicated) for 4--5 consecutive days ([@bib15]; [@bib45]). Mouse weight and ear thickness were monitored daily. Mice were euthanized on the indicated time points after start of treatment (day 0, 5, 7 and 12) PB, Spl, BM and aortas were collected for further analysis.

Adoptive cell transfer experiments {#s4-8}
----------------------------------

Lin^-^CD11b^+^Ly6C^hi^GFP^+^ monocytes were sorted from BM of CD45.2^+^ donors and injected into CD45.1^+^ recipients intravenously (i.v.). In separate experiment wt or *Myd88^-/-^* LinCD45.2^+^CD11b^+^Ly6C^hi^CX~3~CR1^+^ monocytes were used as a donor for transfer. 30 min later PBS or R848 (37.5 µg per mouse) were injected in recipient mice. Two days after transfer Spl, PB and BM were collected and single cell suspension was prepared. After blocking of Fc receptors (anti-mouse CD16/CD32, TruStain fcX from BioLegend), cells were labeled with biotin-conjugated antibody cocktail containing anti-CD45.1 and anti-Lin (anti-CD3, CD19, B220, NK1.1, Ly6G, Ter119) antibodies, anti-biotin magnetic beads and enriched on LS columns (Miltenyi Biotec) according to manufacturer's instructions. CD45.1^neg^Lin^neg^ fraction was collected, stained and analyzed by flow cytometry. Ly6C^lo^ monocytes (CD45.2^+^CD11b^+^GFP^+^Ly6C^lo/-^F4/80^lo^CD11c^lo^CD43^hi^ cells) and macrophages (CD45.2^+^CD11b^+^GFP^+^Ly6C^lo/-^F4/80^hi^CD115^+^ cells) were quantified in Spl, BM and PB as relative frequency of total donor derived CD45.2^+^CD11b^+^GFP^+^ cells. Adoptive transfer experiments in IMQ-treated mice were performed using wt or *N2^ΔMy^* Lin^-^CD45.2^+^CD11b^+^Ly6C^hi^GFP^+^ donor monocytes and Spl, PB and aortas of recipients were analyzed 3 days after transfer.

Quantitative real-time PCR analysis {#s4-9}
-----------------------------------

Total RNA was purified from cell lysates using Nucleospin RNA II kit (Macherey Nagel). After purity and quality check, RNA was transcribed into cDNA employing cDNA synthesis kit (Invitrogen) according to manufacturer's instructions. Quantitative real-time PCR was performed using specific primers for *Nr4a1*: forward, 5'-AGCTTGGGTGTTGATGTTCC-3', reverse, 5'-AATGCGATTCTGCAGCTCTT-3' and *Pou2f2:* forward, 5'-TGCACATGGAGAAGGAAGTG-3', reverse, 5'-AGCTTGGGACAATGGTAAGG-3' and FastStart Essential DNA Green Master on a LightCycler 96 system from Roche according to manufacturer's instructions. Expression of each specific gene was normalized to expression of *Rps9* and calculated by the comparative CT (2^-ΔΔCT^) method ([@bib42]).

Statistical analysis {#s4-10}
--------------------

Results are expressed as mean ± standard error of mean (SEM). N numbers are biological replicates of experiments performed at least three times unless otherwise indicated. Significance of differences was calculated using unpaired, two-tailed Student's *t-*test with confidence interval of 95%. For comparison of multiple experimental groups one-way or two-way ANOVA and Bonferroni's multiple-comparison test was performed.
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**Acceptance summary:**

The authors have explored the processes involved in the fate of LY6C^hi^ monocytes and the factors influencing this process under TLR7-induced inflammation. They show that the Ly6C^hi^ monocyte conversion to Ly6C^lo^ monocytes is dependent on cell intrinsic Notch2 and Myd88 pathway as selective invalidation of Notch2 bias the differentiation of monocytes in steady state and more extensively in inflammatory condition toward circulating macrophages. This is an interesting set of findings, based on sound experiments using a variety of approaches ranging over conditional genetic deletions, cell transfers and cell culture techniques to track these cells in vivo and in vitro.

**Decision letter after peer review:**

Thank you for submitting your article \"Notch and TLR signaling coordinate monocyte cell fate and inflammation\" for consideration by *eLife*. Your article has been reviewed by Satyajit Rath as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Alexandre Boissonnas (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \'in revision at *eLife*\'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

The authors explored the processes involved in the fate of LY6C^hi^ monocytes and the factors influencing this process under TLR7-induced inflammation. They show that the Ly6C^hi^ monocyte conversion to Ly6C^lo^ monocytes is dependent on cell intrinsic Notch2 and Myd88 pathway as selective invalidation of Notch2 bias the differentiation of monocytes in steady state and more extensively in inflammatory condition toward circulating macrophages. This is an interesting paper and the presented experiments are of good quality. This study uses a variety of conditional genetic deletions, cell transfers and cell culture techniques to track these cells in vivo and in vitro.

Essential revisions:

While the editors and reviewers all agreed on the interest of the study, several points need to be addressed to strengthen the study.

The transcriptome analysis presented in Figure 4 is important, but missing Ly6Clow monocytes from wt and myeloid Notch deficient cells under steady state conditions. It would be important to compare the profiles of untreated and IMQ-treated Notch2-deficient cells to dissect the treatment effects from the steady state condition caused by Notch2 deletion.

The authors should provide deletion efficiency in both monocyte subsets, for instance by qRT-PCR for the deleted exon. There is experimental proof that the Cre lox system is not fully efficient in classical monocytes, usually associated to their short life span and likely partial in the ncMo (as confirmed in Gamrekelashvili et al., 2016) and others. This could explain why the PCA analysis detects minimal difference in the Ly6Chigh subset as well as no impact on numbers in Notch2-mutant mice. Hence it is dificult to support the main conclusion that Notch2-mediated decision occurs at the Ly6Chigh level as it is still mostly present. Notch2 could rather regulate the survival of Ly6Clow Mo. This point is slightly discussed in the Discussion section. The efficiency of Notch recombination in Mo subsets after the different treatments must be presented (even if previously published at steady state) to better apprehend this limit.

Lineage tracing is always challenging, and it is difficult to assess whether notch signaling is requested in the differentiation toward a specific lineage or is requested for cell survival. Notch regulated monocyte survival is a well taken point, since also Bcl2 is strongly decreased in Notch2-/- monocytes. Therefore, providing absolute numbers for the in vivo and in vitro experiments (cell numbers instead of %) is absolutely required. In fact, most of the study is based on % (often unclear among which population) which could lead to misinterpretation. The authors should provide absolute numbers per organs along with per mg, whenever possible. For example, \"By comparison, the TLR4 ligand LPS also increased Ly6C^lo^ cell numbers and expression levels of Nr4a1and Pou2f2. However, the absolute conversion rate was lower under LPS and there was no synergy with DLL1 (Figure 1D and E)\". The numbers are not evaluated here neither the conversion rate as long as survival difference cannot be excluded.

The \'unrestrained inflammation\' part either should be experimentally proven our should be completely rephrased (or deleted). The authors state in the abstract that \"the absence of functional Notch2 signaling promotes resident tissue macrophage gene expression (...) resulting in unrestrained systemic inflammation\" that could be interpreted as an overstatement. The inflammatory response shows perturbation in Notch-deficient mice, but not a clear pro-inflammatory shift (see also point below). Accordingly, it is not clear, if the splenomegaly or the \"unrestrained systemic inflammation\" is directly caused by monocytes. LysM-Cre is also active in neutrophils, which similarly express high levels of Notch2 according to immgen and can contribute to the observed phenotype. If the authors want to keep the link of \'Notch2-deficient monocytes cause unrestrained systemic inflammation\' then the authors should perform monocyte (anti-CCR2 treatment) and neutrophil (anti-Ly6G treatment) depletion experiments in IMQ-treated wt and Notch-deficient mice. If the observed splenomegaly in Notch2-deficient mice is reduced to wt levels when treated with CCR2 (but not after Ly6G treatment), it is likely that monocytes are the direct cause.

T0 purity and flow analysis (F4/80, Ly6C,CD43, CD11c CD11b and GFP) of the sorted monocyte from all mouse strains should be provided. Working with bone marrow monocytes can be precarious, as the bone marrow may be contaminated with progenitors (and should be mentioned in the text).

In Figure 3 the authors perform t-SNE analysis based on the Ly6C, CD43, MHCII, F4/80 and CD11c marker set and according to this identified 5 monocyte \'subsets\' (Figure 2C). Please also show the corresponding flow cytometry analysis (dot plots) (especially for PB) to identify these 5 subsets by regular gating and to see intensity of especially F4/80 and MHCII staining in Ly6Chigh and Ly6Clow monocytes in all conditions. In addition, in the gating strategy Figure 3---figure supplement 1C the authors used F4/80 to discriminate CD115+ MF from monocytes. Rose et al., 2011 in Cytometry A showed that splenic monocytes also express F4/80 and that this antigen can be used to identify monocytes. Therefore, it is possible that MF cells in the authors\' gating strategy are contaminated by (probably aged) Ly6C low monocytes that up-regulated F4/80. To counter argue this please show their gated MF in a FACS plot with Ly6C vs CD43.

Consistent with the working hypothesis: Notch deficient LY6C^lo^ monocyte phenotype drastically changes following IMQ Figure 3. Why were Ly6C^lo^ wt and N2 deficient monocytes not examined without IMQ Figure 4? It is important to know how these cells alter from baseline and help distinguish if the effects are IMQ alone, Notch alone or IMQ and Notch.

The conclusion from these studies is in the presence of IMQ and absence of Notch2 LY6C^hi^ cells become more of a \"macrophage\" compared to the natural progression towards LY6C^lo^ monocytes Figure 5A/B. In Figure 5B, c and F what is the phenotype without IMQ. At present, without the controls, it is hard to comment on these experiments.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Notch and TLR signaling coordinate monocyte cell fate and inflammation\" for consideration by *eLife*. Your article has been reviewed by Satyajit Rath as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Alexander Mildner (Reviewer \#2); Alexandre Boissonnas (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

All reviewers and editor agree that the authors have addressed most of the concerns that were raised and included important new data to support their hypothesis. Even though the authors could not perform the important bulk RNA-seq experiment of Notch-deficient Ly6C low monocytes under steady state conditions, they represented (and included in the manuscript) strong reasons for this (especially the mentioned selection bias). However, one last point on survival needs to be addressed and discussed in the revised version of the manuscript.

Annexin V detection ex vivo cannot rule out the reduced survival of Ly6CClow monocyte

Apoptotic cells are not harvested for flow cytometry as the process is not synchronous. Hence, the hypothesis that Notch 2 control Mo survival should not be excluded. This alternative hypothesis is even supported by the absolute count where the number of missing Ly6Clow is not compensated by both MF and DC numbers in Notch 2 deficient in Figure 3. For instance, the difference of 200 cells/µl of Ly6chigh in the blood between WT and N2KO shows a difference of 50 cells /µl of Ly6C^lo^ at day 7 and a difference of 1.5 F4/80^hi^ cells /µl which rather argue for a defect in cell survival and a very weak accumulation of F4/80^hi^ cells in the blood. Similar discrepancy is observed in the spleen. Around 800,000 Ly6C^lo^ cell difference in the spleen for only an extra of 10,000 F4/80^hi^ cells.

Absolute value for adoptive transfer experiment have not been provided. In addition, since bcl2 is strongly down in ko cells, a reduced survival does not necessarily mean a higher apoptosis rate.

The authors need to discuss and state this survival point across the manuscript, whenever necessary.
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Author response

> Summary:
>
> The authors explored the processes involved in the fate of LY6C^hi^ monocytes and the factors influencing this process under TLR7-induced inflammation. They show that the Ly6C^hi^ monocyte conversion to Ly6C^lo^ monocytes is dependent on cell intrinsic Notch2 and Myd88 pathway as selective invalidation of Notch2 bias the differentiation of monocytes in steady state and more extensively in inflammatory condition toward circulating macrophages. This is an interesting paper and the presented experiments are of good quality. This study uses a variety of conditional genetic deletions, cell transfers and cell culture techniques to track these cells in vivo and in vitro.
>
> Essential revisions:
>
> 1\) While the editors and reviewers all agreed on the interest of the study, several points need to be addressed to strengthen the study.
>
> The transcriptome analysis presented in Figure 4 is important, but missing Ly6Clow monocytes from wt and myeloid Notch deficient cells under steady state conditions. It would be important to compare the profiles of untreated and IMQ-treated Notch2-deficient cells to dissect the treatment effects from the steady state condition caused by Notch2 deletion.

We agree that it is important to dissect the impact of Notch2 loss-of-function and IMQ treatment and that it would be desirable to also compare the Ly6C^lo^ baseline sets. However, there are technical/methodological issues that unfortunately prevented this. Due to the low numbers of circulating cells in mutant mice, we failed to get enough material for sequencing and could not include this condition in the analysis. More specifically, in two independent sorts, each time pooling three mutant mice, we retrieved only 8278 and 15300 Ly6C^lo^ cells, which are several orders below the required input of 100000 cells for sequencing. Also, there seems to be a strong selection bias in Ly6C^lo^ cells against Notch2 loss of function at steady state, based on Notch2 expression data by flow cytometry (see also point 2 below). As a consequence, while the original Ly6C^hi^ monocytes -as a source of Ly6C^lo^ development- show a 50% reduction in Notch2 expression, the few remaining Ly6C^lo^ cells in Notch2 mutant mice show roughly the same level of Notch2 expression as control mice (Figure 5---figure supplement 2C), arguing that only Notch2 competent cells complete conversion to Ly6C^lo^ cells at the steady state. A comparison might therefore not be representative of Ly6C^lo^ cells with Notch2 loss of function. We have included a discussion on the limitations of the study in the Discussion section (Due to the low number Ly6C^lo^ monocytes at the steady state we were not able to compare baseline expression profiles, which is a limitation of this analysis.)

While we are not able to provide baseline transcriptome analysis, we would like to point out that our cell phenotype and population analysis by flow cytometry clearly shows effects of Notch2 deletion and IMQ-treatment on monocytes, separately and in combination, including baseline data (Figure 3 and Figure 3---figure supplement 2). In particular, there is no evidence of a significant F4/80^hi^ monocyte population in Notch2 deficient mice under steady state conditions, but only with treatment of Notch2 knock-out mice, demonstrating that development of F4/80^hi^ monocytes and macrophages occurs only under inflammatory conditions in Notch2 deficient mice. Also, upregulation of macrophage markers Mertk and CD64 was not observed to a relevant degree in baseline Ly6C^lo^ cells from Notch deficient mice. Thus, a major cell type characteristic of the mutant response to IMQ is not observed under baseline conditions. This is supported by our previous findings that adoptive transfer of Notch2 deficient Ly6C^hi^ monocytes under steady state conditions (Gamrekelashvili et al., 2016) does not lead to development of F4/80^hi^ cells as observed in current study (Figure 5E).

> 2\) The authors should provide deletion efficiency in both monocyte subsets, for instance by qRT-PCR for the deleted exon. There is experimental proof that the Cre lox system is not fully efficient in classical monocytes, usually associated to their short life span and likely partial in the ncMo (as confirmed in Gamrekelashvili et al., 2016) and others. This could explain why the PCA analysis detects minimal difference in the Ly6Chigh subset as well as no impact on numbers in Notch2-mutant mice. Hence it is dificult to support the main conclusion that Notch2-mediated decision occurs at the Ly6Chigh level as it is still mostly present. Notch2 could rather regulate the survival of Ly6Clow Mo. This point is slightly discussed in the Discussion section. The efficiency of Notch recombination in Mo subsets after the different treatments must be presented (even if previously published at steady state) to better apprehend this limit.

Again, we agree that data on deletion efficiency are important to put the presented data on Ly6C^hi^ and Ly6C^lo^ monocytes in perspective. We have analyzed deletion efficiency of Notch2 and Notch target gene expression by transcriptome analysis and Notch2 surface expression by flow cytometry, the data are summarized in Figure 5---figure supplement 2 and are reported in subsection "Notch2 regulates monocyte cell fate decisions during inflammation".

With respect to Ly6C^hi^ monocytes, our new analysis in these cells shows that there is a 40-50% reduction of Notch2 expression by sequence reads and by surface staining (Figure 5---figure supplement 2A, C). Furthermore, there is \> 50% reduction of Notch target gene Hes1, suggesting sufficient targeting and functional impairment of Notch2 in Ly6C^hi^ monocytes. In light that baseline Notch signaling activity seems to be low in Ly6C^hi^ monocytes and only significantly increases in Ly6C^lo^ monocytes (see Hes1 expression in Figure 5---figure supplement 2B and Gamrekelashvili, 2016, Figure. 2A) this is consistent with an interpretation that Notch2 impairment does not significantly influence Ly6C^hi^ gene expression or numbers, since it seems to be not particularly active. It also supports the argument that while Ly6C^hi^ cells per se do not depend on fully functional Notch2 signaling, conversion to Ly6C^lo^ cells depends on Notch2, which might happen at the level of Ly6C^hi^ cells or below. However, we also agree that partial targeting of Notch2 is an alternative explanation for the small differences seen in PCA analysis. We have clarified this in the Discussion section.

With respect to Ly6C^lo^ cells, there is minor reduction of Notch2 in the few remaining mutant cells at baseline, but more efficient reduction of Notch2 in IMQ mice, to levels seen in Ly6C^hi^ cells (Figure 5---figure supplement 2C). This would be in line with selection pressure against loss-of-function (see above) at baseline, either because of inability to initiate conversion (in line with our data on adoptive transfer of Ly6C^hi^ monocytes, supporting that decisions that place at the level of Ly6C^hi^ cells) or enhanced cell death in Ly6C^lo^ monocytes during/after conversion. The presence of IMQ, in contrast, seems to allow for the generation of more Notch2 deficient cells, which is in line with our in vitro data showing that R848 treatment in the absence of Notch stimulation also increases Ly6C^lo^ cell numbers.

We also addressed the issue of cell death raised above. There was no evidence of increased cell death in mutant cells compared to wt cells in all relevant cell types analyzed (Figure 5L, M. See point 3 below). We have extended the Results section and Discussion section accordingly.

> 3\) Lineage tracing is always challenging, and it is difficult to assess whether notch signaling is requested in the differentiation toward a specific lineage or is requested for cell survival. Notch regulated monocyte survival is a well taken point, since also Bcl2 is strongly decreased in Notch2-/- monocytes. Therefore, providing absolute numbers for the in vivo and in vitro experiments (cell numbers instead of %) is absolutely required. In fact, most of the study is based on % (often unclear among which population) which could lead to misinterpretation. The authors should provide absolute numbers per organs along with per mg, whenever possible. For example, \"By comparison, the TLR4 ligand LPS also increased Ly6C^lo^ cell numbers and expression levels of Nr4a1and Pou2f2. However, the absolute conversion rate was lower under LPS and there was no synergy with DLL1 (Figure 1D and E)\". The numbers are not evaluated here neither the conversion rate as long as survival difference cannot be excluded.

We now provide absolute cell numbers for all datasets in addition to rel. quantification (Figure 1B, D, F, G for in vitro studies. Figure 5H, Figure 3---figure supplement 3A-C for in vivo studies). In fact, for the in vivo data we had presented the data upon initial submission in Figure S5 and Figure 5K. In summary, the absolute cell numbers match the relative cell frequency analysis, thus supporting our conclusions.

With respect to survival, we present new data on cell death analysis (see above), which did not show evidence for increased cell death, supporting regulation of conversion as the main mechanism.

> 4\) The \'unrestrained inflammation\' part either should be experimentally proven our should be completely rephrased (or deleted). The authors state in the abstract that \"the absence of functional Notch2 signaling promotes resident tissue macrophage gene expression (...) resulting in unrestrained systemic inflammation\" that could be interpreted as an overstatement. The inflammatory response shows perturbation in Notch-deficient mice, but not a clear pro-inflammatory shift (see also point below). Accordingly, it is not clear, if the splenomegaly or the \"unrestrained systemic inflammation\" is directly caused by monocytes. LysM-Cre is also active in neutrophils, which similarly express high levels of Notch2 according to immgen and can contribute to the observed phenotype. If the authors want to keep the link of \'Notch2-deficient monocytes cause unrestrained systemic inflammation\' then the authors should perform monocyte (anti-CCR2 treatment) and neutrophil (anti-Ly6G treatment) depletion experiments in IMQ-treated wt and Notch-deficient mice. If the observed splenomegaly in Notch2-deficient mice is reduced to wt levels when treated with CCR2 (but not after Ly6G treatment), it is likely that monocytes are the direct cause.

We have followed the advice and have altered the wording to 'aberrant inflammation', indicating that the mutant response differs from the wt response. See Results section and Discussion section. We also agree that the relevance of the changes is not clear in this somewhat artificial model. However, the phenomenon itself should be reported and the relevance and possible disease context should be studied in further studies. We have added this point to the Discussion section.

> 5\) T0 purity and flow analysis (F4/80, Ly6C,CD43, CD11c CD11b and GFP) of the sorted monocyte from all mouse strains should be provided. Working with bone marrow monocytes can be precarious, as the bone marrow may be contaminated with progenitors (and should be mentioned in the text).

As requested, we have included the monocyte sorting strategy, T0 purity and analysis in Figure 1---figure supplement 1 A-D and Figure 2---figure supplement 1A and B. Overall, there is very high purity. Furthermore, our targeting strategy does not influence progenitors (see above and Gamrekelashvili, 2016), therefore, we suggest it is an unlikely confounder for the different outcomes between wt and ko after transfer. However, it could be a confounder concerning cell fates in general, e. g. DC-like populations in the spleen. We discuss the potential confounder of progenitor contamination in the text (Discussion section).

> 6\) In Figure 3 the authors perform t-SNE analysis based on the Ly6C, CD43, MHCII, F4/80 and CD11c marker set and according to this identified 5 monocyte \'subsets\' (Figure 2C). Please also show the corresponding flow cytometry analysis (dot plots) (especially for PB) to identify these 5 subsets by regular gating and to see intensity of especially F4/80 and MHCII staining in Ly6Chigh and Ly6Clow monocytes in all conditions. In addition, in the gating strategy Figure 3---figure supplement 21C the authors used F4/80 to discriminate CD115+ MF from monocytes. Rose et al., 2011 in Cytometry A showed that splenic monocytes also express F4/80 and that this antigen can be used to identify monocytes. Therefore, it is possible that MF cells in the authors\' gating strategy are contaminated by (probably aged) Ly6C low monocytes that up-regulated F4/80. To counter argue this please show their gated MF in a FACS plot with Ly6C vs CD43.

Our initial t-SNE analysis was performed as a global screening for perturbations in the 'monocytes pool' (Live CD45^+^Lin^neg^CD11b^+^CX3CR1-GFP^+^) and we use this rather crude method to inform strategies for further analysis. However, the detailed subset analysis and quantification depicted in submission Figure 3E,F, Figure 5J,K and S3A-D had already been performed with a regular gating strategy shown in S2C.

Following the advice we now provide additional sets of analysis using regular gating in all conditions and show intensities of F4/80, MHC-II and CD43 (Figure 3---figure supplement 2A and B). We also provide FACS plots of cell populations and show Ly6C vs CD43 expression, which demonstrate that the expanded F4/80^hi^ population in mutant mice does not express the Ly6C^lo^ monocyte marker CD43 (Figure 3---figure supplement 2B). In addition, we demonstrate by flow cytometry expression of Mertk and CD64, prototypical macrophage genes, in Notch2 knock-out Ly6C^lo^ cells (Figure 5B-D). Furthermore, N2^ΔMy^ cells show enrichment of prototypical macrophage gene sets by GSEA (Figure 5A and Supplementary file 4 and Supplementary file 5). The combined data thus suggest at least partial acquisition of a macrophage phenotype by N2^ΔMy^ cells, and our argument is based on several lines of evidence. However, since the transition of monocyte to monocyte-derived macrophage state should be gradual process, and since we observed these cells mostly in the blood, which is an unusual place for classical MF but more in line with circulating monocytes, we changed the description to F4/80^high^CD115^+^ monocytes and to F4/80^high^MerTK^+^ (FM^+^) monocytes later in the text as suggested by the reviewer.

> 7\) Consistent with the working hypothesis: Notch deficient LY6C^lo^ monocyte phenotype drastically changes following IMQ Figure 3. Why were Ly6C^lo^ wt and N2 deficient monocytes not examined without IMQ Figure 4? It is important to know how these cells alter from baseline and help distinguish if the effects are IMQ alone, Notch alone or IMQ and Notch.

This indeed is a limitation of our study (see reply to point no. 1).

> 8\) The conclusion from these studies is in the presence of IMQ and absence of Notch2 LY6C^hi^ cells become more of a \"macrophage\" compared to the natural progression towards LY6C^lo^ monocytes Figure 5A/B. In Figure 5B, c and F what is the phenotype without IMQ. At present, without the controls, it is hard to comment on these experiments.

In our previous study (Gamrekelashvili et al., 2016) we have already addressed the differentiation of Ly6C^hi^ monocytes into Ly6C^lo^ monocytes under steady state conditions and have shown that this process is impaired in the absence of Notch2. In the steady state, Notch2 deficient mice mostly develop a MHCII+CD11c-CD43- population of monocytes, which do not express F4/80 (Figure 3---figure supplement 2B), MerTK or CD64 to a relevant extent (Figure 5B-D), and thus do not show the FM^+^ phenotype. These findings were recapitulated in adoptive transfer experiments at steady state (Gamrekelashvili et al., 2016) and with IMQ treatment (Figure 5E, G). Therefore, significant expansion of FM^+^ monocytes occurs only with IMQ treatment.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Summary:
>
> All reviewers and editor agree that the authors have addressed most of the concerns that were raised and included important new data to support their hypothesis. Even though the authors could not perform the important bulk RNA-seq experiment of Notch-deficient Ly6C low monocytes under steady state conditions, they represented (and included in the manuscript) strong reasons for this (especially the mentioned selection bias). However, one last point on survival needs to be addressed and discussed in the revised version of the manuscript.
>
> Annexin V detection ex vivo cannot rule out the reduced survival of Ly6CClow monocyte
>
> Apoptotic cells are not harvested for flow cytometry as the process is not synchronous. Hence, the hypothesis that Notch 2 control Mo survival should not be excluded. This alternative hypothesis is even supported by the absolute count where the number of missing Ly6Clow is not compensated by both MF and DC numbers in Notch 2 deficient in Figure 3. For instance, the difference of 200 cells/µl of Ly6chigh in the blood between WT and N2KO shows a difference of 50 cells /µl of Ly6C^lo^ at day 7 and a difference of 1.5 F4/80^hi^ cells /µl which rather argue for a defect in cell survival and a very weak accumulation of F4/80^hi^ cells in the blood. Similar discrepancy is observed in the spleen. Around 800,000 Ly6C^lo^ cell difference in the spleen for only an extra of 10,000 F4/80^hi^ cells.
>
> Absolute value for adoptive transfer experiment have not been provided. In addition, since bcl2 is strongly down in ko cells, a reduced survival does not necessarily mean a higher apoptosis rate.
>
> The authors need to discuss and state this survival point across the manuscript, whenever necessary.

In response to one reviewer, we added an extended discussion on the issue of cell survival. Over one paragraph, we now discuss the possibility of regulation of cell survival as an additional mechanism to explain the Notch2 loss-of-function phenotype:

In the case of Nr4a1 loss-of-function the reduced numbers of Ly6C^lo^ monocytes are due to increased apoptosis (Hanna et al., 2011). Although we did not find evidence for increased apoptosis due to Notch2-deficiency, our data do not exclude the possibility that regulation of cell survival by Notch2 contributes to the observed phenotype. In fact, two lines of the evidence suggest that regulation of cell survival might act synergistically to cell fate choices: first, in absolute numbers, there is no compensation by alternative cell fates for the number of lacking Ly6C^lo^ monocytes in the blood or spleen of N2^ΔMy^ mice; second, expression of Bcl2, a strong regulator of cell survival, is downregulated in IMQ-treated N2^ΔMy^ Ly6C^lo^ cells as compared to controls.
